25 June 2009

Flamel Technologies Announces Two New Feasibility Agreements

Lyon, France – June 25, 2009 – Flamel Technologies S.A. (NASDAQ: FLML) today announced
that it has entered into two new feasibility agreements to apply its Medusa® platform with two
additional companies. One program is designed to deliver a controlled release of a marketed
hormone; the other is a Medusa formulation of a therapeutic peptide. The Company is currently
working on nineteen feasibility programs with fifteen partner companies. These products are in
addition to the new product collaborations announced earlier this week.
Stephen H. Willard, Flamel Technologies’ chief executive officer, commented, “With these two new
agreements, we are continuing to diversify our revenue base and add additional potential catalysts for
substantial growth in the years to come. Our success in executing this diversified strategy is a
testament to the strength of our drug delivery technology, which offers many advantages beyond
control release. These include the ability to dramatically increase solubility, side-effect reduction, and
the ability to deliver drugs which can not currently be delivered by other methods. Our financial
model is quite efficient, and it is intended to drive significant value for shareholders as these programs
progress.”
Flamel Technologies, S.A. is a biopharmaceutical company principally engaged in the development of
two unique polymer-based delivery technologies for medical applications. Micropump is a controlled
release and taste-masking technology for the oral administration of small molecule drugs. Flamel's
Medusa technology is designed to deliver controlled-release formulations of therapeutic proteins,
peptides, and other molecules.